Arcturus undeterred by low neutralizing titers from COVID vaccine in Phase I; shares slide

Arcturus believes cellular responses induced by its COVID-19 vaccine candidate will compensate for the underwhelming neutralizing antibody levels in its interim Phase I/II data.

The RNA company’s shares fell 39% after hours Monday, and on Tuesday sank by 54% to $42.36  as investors further digested the data and Wall Street analysts downgraded the stock...